CN114702591A - Preparation technology of adult cell-derived organoid - Google Patents
Preparation technology of adult cell-derived organoid Download PDFInfo
- Publication number
- CN114702591A CN114702591A CN202210539273.8A CN202210539273A CN114702591A CN 114702591 A CN114702591 A CN 114702591A CN 202210539273 A CN202210539273 A CN 202210539273A CN 114702591 A CN114702591 A CN 114702591A
- Authority
- CN
- China
- Prior art keywords
- gsk
- monoclonal antibody
- beta
- antibody
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 210000002220 organoid Anatomy 0.000 title abstract description 17
- 238000005516 engineering process Methods 0.000 title abstract description 8
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims abstract description 34
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 claims abstract description 34
- 210000000056 organ Anatomy 0.000 claims abstract description 16
- 210000001178 neural stem cell Anatomy 0.000 claims abstract description 10
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 8
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 27
- 230000004069 differentiation Effects 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 53
- 108090000623 proteins and genes Proteins 0.000 abstract description 12
- 239000000427 antigen Substances 0.000 abstract description 9
- 102000036639 antigens Human genes 0.000 abstract description 9
- 108091007433 antigens Proteins 0.000 abstract description 9
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 230000014509 gene expression Effects 0.000 abstract description 8
- 210000004408 hybridoma Anatomy 0.000 abstract description 6
- 238000012216 screening Methods 0.000 abstract description 6
- 108090000144 Human Proteins Proteins 0.000 abstract description 2
- 102000003839 Human Proteins Human genes 0.000 abstract description 2
- 239000002609 medium Substances 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 102000001267 GSK3 Human genes 0.000 description 11
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 11
- 239000012634 fragment Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 101150059062 apln gene Proteins 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000003716 mesoderm Anatomy 0.000 description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 description 3
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 description 3
- 101000652332 Homo sapiens Transcription factor SOX-1 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 102100030248 Transcription factor SOX-1 Human genes 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 210000000885 nephron Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 210000001811 primitive streak Anatomy 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002620 ureteric effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000003957 Fibroblast growth factor 9 Human genes 0.000 description 2
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 description 2
- 108010001483 Glycogen Synthase Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101001032567 Homo sapiens Glycogen synthase kinase-3 beta Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000008730 Nestin Human genes 0.000 description 2
- 108010088225 Nestin Proteins 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000013814 Wnt Human genes 0.000 description 2
- 108050003627 Wnt Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- -1 etc.) Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 108010054155 lysyllysine Proteins 0.000 description 2
- 210000005055 nestin Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- UPMFZISCCZSDND-JJKGCWMISA-M sodium gluconate Chemical compound [Na+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O UPMFZISCCZSDND-JJKGCWMISA-M 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 238000012605 2D cell culture Methods 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 1
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 1
- BEMGNWZECGIJOI-WDSKDSINSA-N Ala-Gly-Glu Chemical compound [H]N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O BEMGNWZECGIJOI-WDSKDSINSA-N 0.000 description 1
- RZZMZYZXNJRPOJ-BJDJZHNGSA-N Ala-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](C)N RZZMZYZXNJRPOJ-BJDJZHNGSA-N 0.000 description 1
- MSWSRLGNLKHDEI-ACZMJKKPSA-N Ala-Ser-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O MSWSRLGNLKHDEI-ACZMJKKPSA-N 0.000 description 1
- NZGRHTKZFSVPAN-BIIVOSGPSA-N Ala-Ser-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N NZGRHTKZFSVPAN-BIIVOSGPSA-N 0.000 description 1
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 1
- SQKPKIJVWHAWNF-DCAQKATOSA-N Arg-Asp-Lys Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O SQKPKIJVWHAWNF-DCAQKATOSA-N 0.000 description 1
- LVMUGODRNHFGRA-AVGNSLFASA-N Arg-Leu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O LVMUGODRNHFGRA-AVGNSLFASA-N 0.000 description 1
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 1
- BSYKSCBTTQKOJG-GUBZILKMSA-N Arg-Pro-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BSYKSCBTTQKOJG-GUBZILKMSA-N 0.000 description 1
- HGKHPCFTRQDHCU-IUCAKERBSA-N Arg-Pro-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O HGKHPCFTRQDHCU-IUCAKERBSA-N 0.000 description 1
- MYTHOBCLNIOFBL-SRVKXCTJSA-N Asn-Ser-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MYTHOBCLNIOFBL-SRVKXCTJSA-N 0.000 description 1
- DBWYWXNMZZYIRY-LPEHRKFASA-N Asp-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N)C(=O)O DBWYWXNMZZYIRY-LPEHRKFASA-N 0.000 description 1
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 1
- KYQNAIMCTRZLNP-QSFUFRPTSA-N Asp-Ile-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O KYQNAIMCTRZLNP-QSFUFRPTSA-N 0.000 description 1
- WMLFFCRUSPNENW-ZLUOBGJFSA-N Asp-Ser-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O WMLFFCRUSPNENW-ZLUOBGJFSA-N 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- DCXGXDGGXVZVMY-GHCJXIJMSA-N Cys-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CS DCXGXDGGXVZVMY-GHCJXIJMSA-N 0.000 description 1
- WVJHEDOLHPZLRV-CIUDSAMLSA-N Cys-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N WVJHEDOLHPZLRV-CIUDSAMLSA-N 0.000 description 1
- RESAHOSBQHMOKH-KKUMJFAQSA-N Cys-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CS)N RESAHOSBQHMOKH-KKUMJFAQSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- JMIFGARJSWXZSH-UHFFFAOYSA-N DMH1 Chemical compound C1=CC(OC(C)C)=CC=C1C1=CN2N=CC(C=3C4=CC=CC=C4N=CC=3)=C2N=C1 JMIFGARJSWXZSH-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- XOKGKOQWADCLFQ-GARJFASQSA-N Gln-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XOKGKOQWADCLFQ-GARJFASQSA-N 0.000 description 1
- XJKAKYXMFHUIHT-AUTRQRHGSA-N Gln-Glu-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N XJKAKYXMFHUIHT-AUTRQRHGSA-N 0.000 description 1
- NSORZJXKUQFEKL-JGVFFNPUSA-N Gln-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCC(=O)N)N)C(=O)O NSORZJXKUQFEKL-JGVFFNPUSA-N 0.000 description 1
- ZEEPYMXTJWIMSN-GUBZILKMSA-N Gln-Lys-Ser Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@@H](N)CCC(N)=O ZEEPYMXTJWIMSN-GUBZILKMSA-N 0.000 description 1
- GLWXKFRTOHKGIT-ACZMJKKPSA-N Glu-Asn-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GLWXKFRTOHKGIT-ACZMJKKPSA-N 0.000 description 1
- HVYWQYLBVXMXSV-GUBZILKMSA-N Glu-Leu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HVYWQYLBVXMXSV-GUBZILKMSA-N 0.000 description 1
- DNPCBMNFQVTHMA-DCAQKATOSA-N Glu-Leu-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O DNPCBMNFQVTHMA-DCAQKATOSA-N 0.000 description 1
- IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 1
- SUIAHERNFYRBDZ-GVXVVHGQSA-N Glu-Lys-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O SUIAHERNFYRBDZ-GVXVVHGQSA-N 0.000 description 1
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- ZQIMMEYPEXIYBB-IUCAKERBSA-N Gly-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN ZQIMMEYPEXIYBB-IUCAKERBSA-N 0.000 description 1
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 1
- HAXARWKYFIIHKD-ZKWXMUAHSA-N Gly-Ile-Ser Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HAXARWKYFIIHKD-ZKWXMUAHSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- JSLVAHYTAJJEQH-QWRGUYRKSA-N Gly-Ser-Phe Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JSLVAHYTAJJEQH-QWRGUYRKSA-N 0.000 description 1
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 1
- KOYUSMBPJOVSOO-XEGUGMAKSA-N Gly-Tyr-Ile Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KOYUSMBPJOVSOO-XEGUGMAKSA-N 0.000 description 1
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 1
- KSOBNUBCYHGUKH-UWVGGRQHSA-N Gly-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN KSOBNUBCYHGUKH-UWVGGRQHSA-N 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- SLQVFYWBGNNOTK-BYULHYEWSA-N Ile-Gly-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N SLQVFYWBGNNOTK-BYULHYEWSA-N 0.000 description 1
- UFRXVQGGPNSJRY-CYDGBPFRSA-N Ile-Met-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N UFRXVQGGPNSJRY-CYDGBPFRSA-N 0.000 description 1
- NAFIFZNBSPWYOO-RWRJDSDZSA-N Ile-Thr-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N NAFIFZNBSPWYOO-RWRJDSDZSA-N 0.000 description 1
- JSLIXOUMAOUGBN-JUKXBJQTSA-N Ile-Tyr-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N JSLIXOUMAOUGBN-JUKXBJQTSA-N 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- RRSLQOLASISYTB-CIUDSAMLSA-N Leu-Cys-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(O)=O RRSLQOLASISYTB-CIUDSAMLSA-N 0.000 description 1
- WIDZHJTYKYBLSR-DCAQKATOSA-N Leu-Glu-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WIDZHJTYKYBLSR-DCAQKATOSA-N 0.000 description 1
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 1
- CPONGMJGVIAWEH-DCAQKATOSA-N Leu-Met-Ala Chemical compound CSCC[C@H](NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](C)C(O)=O CPONGMJGVIAWEH-DCAQKATOSA-N 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- LJBVRCDPWOJOEK-PPCPHDFISA-N Leu-Thr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LJBVRCDPWOJOEK-PPCPHDFISA-N 0.000 description 1
- AXVIGSRGTMNSJU-YESZJQIVSA-N Leu-Tyr-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N AXVIGSRGTMNSJU-YESZJQIVSA-N 0.000 description 1
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 1
- DNEJSAIMVANNPA-DCAQKATOSA-N Lys-Asn-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DNEJSAIMVANNPA-DCAQKATOSA-N 0.000 description 1
- OVIVOCSURJYCTM-GUBZILKMSA-N Lys-Asp-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OVIVOCSURJYCTM-GUBZILKMSA-N 0.000 description 1
- CRNNMTHBMRFQNG-GUBZILKMSA-N Lys-Glu-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N CRNNMTHBMRFQNG-GUBZILKMSA-N 0.000 description 1
- PBLLTSKBTAHDNA-KBPBESRZSA-N Lys-Gly-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PBLLTSKBTAHDNA-KBPBESRZSA-N 0.000 description 1
- MUXNCRWTWBMNHX-SRVKXCTJSA-N Lys-Leu-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O MUXNCRWTWBMNHX-SRVKXCTJSA-N 0.000 description 1
- DIBZLYZXTSVGLN-CIUDSAMLSA-N Lys-Ser-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O DIBZLYZXTSVGLN-CIUDSAMLSA-N 0.000 description 1
- DRRXXZBXDMLGFC-IHRRRGAJSA-N Lys-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN DRRXXZBXDMLGFC-IHRRRGAJSA-N 0.000 description 1
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 1
- RIPJMCFGQHGHNP-RHYQMDGZSA-N Lys-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)N)O RIPJMCFGQHGHNP-RHYQMDGZSA-N 0.000 description 1
- RPEPZINUYHUBKG-FXQIFTODSA-N Met-Cys-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O RPEPZINUYHUBKG-FXQIFTODSA-N 0.000 description 1
- VOOINLQYUZOREH-SRVKXCTJSA-N Met-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N VOOINLQYUZOREH-SRVKXCTJSA-N 0.000 description 1
- JACAKCWAOHKQBV-UWVGGRQHSA-N Met-Gly-Lys Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN JACAKCWAOHKQBV-UWVGGRQHSA-N 0.000 description 1
- WTHGNAAQXISJHP-AVGNSLFASA-N Met-Lys-Val Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O WTHGNAAQXISJHP-AVGNSLFASA-N 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- YRKFKTQRVBJYLT-CQDKDKBSSA-N Phe-Ala-His Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=CC=C1 YRKFKTQRVBJYLT-CQDKDKBSSA-N 0.000 description 1
- AFNJAQVMTIQTCB-DLOVCJGASA-N Phe-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 AFNJAQVMTIQTCB-DLOVCJGASA-N 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- LSIWVWRUTKPXDS-DCAQKATOSA-N Pro-Gln-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O LSIWVWRUTKPXDS-DCAQKATOSA-N 0.000 description 1
- CFVRJNZJQHDQPP-CYDGBPFRSA-N Pro-Ile-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 CFVRJNZJQHDQPP-CYDGBPFRSA-N 0.000 description 1
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- MWMKFWJYRRGXOR-ZLUOBGJFSA-N Ser-Ala-Asn Chemical compound N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(N)=O)C)CO MWMKFWJYRRGXOR-ZLUOBGJFSA-N 0.000 description 1
- JPIDMRXXNMIVKY-VZFHVOOUSA-N Ser-Ala-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPIDMRXXNMIVKY-VZFHVOOUSA-N 0.000 description 1
- MIJWOJAXARLEHA-WDSKDSINSA-N Ser-Gly-Glu Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O MIJWOJAXARLEHA-WDSKDSINSA-N 0.000 description 1
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- VVKVHAOOUGNDPJ-SRVKXCTJSA-N Ser-Tyr-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VVKVHAOOUGNDPJ-SRVKXCTJSA-N 0.000 description 1
- OQSQCUWQOIHECT-YJRXYDGGSA-N Ser-Tyr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OQSQCUWQOIHECT-YJRXYDGGSA-N 0.000 description 1
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 description 1
- YSXYEJWDHBCTDJ-DVJZZOLTSA-N Thr-Gly-Trp Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O YSXYEJWDHBCTDJ-DVJZZOLTSA-N 0.000 description 1
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 1
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 1
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 1
- MXDOAJQRJBMGMO-FJXKBIBVSA-N Thr-Pro-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O MXDOAJQRJBMGMO-FJXKBIBVSA-N 0.000 description 1
- XZUBGOYOGDRYFC-XGEHTFHBSA-N Thr-Ser-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(O)=O XZUBGOYOGDRYFC-XGEHTFHBSA-N 0.000 description 1
- VYVBSMCZNHOZGD-RCWTZXSCSA-N Thr-Val-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O VYVBSMCZNHOZGD-RCWTZXSCSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- RPVDDQYNBOVWLR-HOCLYGCPSA-N Trp-Gly-Leu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O RPVDDQYNBOVWLR-HOCLYGCPSA-N 0.000 description 1
- ILDJYIDXESUBOE-HSCHXYMDSA-N Trp-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N ILDJYIDXESUBOE-HSCHXYMDSA-N 0.000 description 1
- PKZIWSHDJYIPRH-JBACZVJFSA-N Trp-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKZIWSHDJYIPRH-JBACZVJFSA-N 0.000 description 1
- QHEGAOPHISYNDF-XDTLVQLUSA-N Tyr-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QHEGAOPHISYNDF-XDTLVQLUSA-N 0.000 description 1
- MVFQLSPDMMFCMW-KKUMJFAQSA-N Tyr-Leu-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O MVFQLSPDMMFCMW-KKUMJFAQSA-N 0.000 description 1
- JXGUUJMPCRXMSO-HJOGWXRNSA-N Tyr-Phe-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 JXGUUJMPCRXMSO-HJOGWXRNSA-N 0.000 description 1
- UMSZZGTXGKHTFJ-SRVKXCTJSA-N Tyr-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UMSZZGTXGKHTFJ-SRVKXCTJSA-N 0.000 description 1
- MWUYSCVVPVITMW-IGNZVWTISA-N Tyr-Tyr-Ala Chemical compound C([C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 MWUYSCVVPVITMW-IGNZVWTISA-N 0.000 description 1
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 1
- GZLGNNHEHXBCBI-UHFFFAOYSA-L [Na+].[Na+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O Chemical compound [Na+].[Na+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O GZLGNNHEHXBCBI-UHFFFAOYSA-L 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- GEWYFWXMYWWLHW-UHFFFAOYSA-N azanium;octanoate Chemical compound [NH4+].CCCCCCCC([O-])=O GEWYFWXMYWWLHW-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- KNKDZWFHOIKECV-UHFFFAOYSA-L dipotassium 2,3,4-trihydroxy-4-oxobutanoate Chemical compound [K+].[K+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O KNKDZWFHOIKECV-UHFFFAOYSA-L 0.000 description 1
- OQOQSRMIBLJVHE-UHFFFAOYSA-L dipotassium 2-hydroxy-2-oxoacetate Chemical compound [K+].[K+].OC(=O)C(O)=O.[O-]C(=O)C([O-])=O OQOQSRMIBLJVHE-UHFFFAOYSA-L 0.000 description 1
- WGFMTHGYKYEDHF-UHFFFAOYSA-L disodium 2-hydroxy-2-oxoacetate Chemical compound [Na+].[Na+].OC(=O)C(O)=O.[O-]C(=O)C([O-])=O WGFMTHGYKYEDHF-UHFFFAOYSA-L 0.000 description 1
- SILCDLWESNHZKB-UHFFFAOYSA-L disodium 4-hydroxy-4-oxobutanoate Chemical compound [Na+].[Na+].OC(=O)CCC([O-])=O.OC(=O)CCC([O-])=O SILCDLWESNHZKB-UHFFFAOYSA-L 0.000 description 1
- MYSDBRXBYJKGLB-WOGKQDBSSA-L disodium;(e)-but-2-enedioate;(e)-but-2-enedioic acid Chemical compound [Na+].[Na+].OC(=O)\C=C\C(O)=O.[O-]C(=O)\C=C\C([O-])=O MYSDBRXBYJKGLB-WOGKQDBSSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010019832 glycyl-asparaginyl-glycine Proteins 0.000 description 1
- 108010026364 glycyl-glycyl-leucine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 102000048346 human GSK3B Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 108010053062 lysyl-arginyl-phenylalanyl-lysine Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- LCPMNMXCIHBTEX-UHFFFAOYSA-M potassium;2-hydroxypropanoate;2-hydroxypropanoic acid Chemical compound [K+].CC(O)C(O)=O.CC(O)C([O-])=O LCPMNMXCIHBTEX-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- KYOYLUVYCHVYGC-BUOKYLHBSA-M sodium (E)-but-2-enedioic acid (E)-4-hydroxy-4-oxobut-2-enoate Chemical compound [Na+].OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C([O-])=O KYOYLUVYCHVYGC-BUOKYLHBSA-M 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- LLVQEXSQFBTIRD-UHFFFAOYSA-M sodium;2,3,4-trihydroxy-4-oxobutanoate;hydrate Chemical compound O.[Na+].OC(=O)C(O)C(O)C([O-])=O LLVQEXSQFBTIRD-UHFFFAOYSA-M 0.000 description 1
- KMPHTYSTEHXSTL-UHFFFAOYSA-M sodium;2-hydroxypropanoate;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O.CC(O)C([O-])=O KMPHTYSTEHXSTL-UHFFFAOYSA-M 0.000 description 1
- VDZDAHYKYRVHJR-UHFFFAOYSA-M sodium;2-hydroxypropanoate;hydrate Chemical compound [OH-].[Na+].CC(O)C(O)=O VDZDAHYKYRVHJR-UHFFFAOYSA-M 0.000 description 1
- OESFSXYRSCBAQJ-UHFFFAOYSA-M sodium;3-carboxy-3,5-dihydroxy-5-oxopentanoate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC([O-])=O OESFSXYRSCBAQJ-UHFFFAOYSA-M 0.000 description 1
- DGPIGKCOQYBCJH-UHFFFAOYSA-M sodium;acetic acid;hydroxide Chemical compound O.[Na+].CC([O-])=O DGPIGKCOQYBCJH-UHFFFAOYSA-M 0.000 description 1
- VBGUQBPWJMPQBI-UHFFFAOYSA-M sodium;butanedioic acid;4-hydroxy-4-oxobutanoate Chemical compound [Na+].OC(=O)CCC(O)=O.OC(=O)CCC([O-])=O VBGUQBPWJMPQBI-UHFFFAOYSA-M 0.000 description 1
- JISIBLCXFLGVJX-UHFFFAOYSA-M sodium;butanedioic acid;hydroxide Chemical compound [OH-].[Na+].OC(=O)CCC(O)=O JISIBLCXFLGVJX-UHFFFAOYSA-M 0.000 description 1
- KIJIBEBWNNLSKE-UHFFFAOYSA-M sodium;oxalic acid;hydroxide Chemical compound [OH-].[Na+].OC(=O)C(O)=O KIJIBEBWNNLSKE-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- JYXKLAOSCQDVIX-NFMYELBMSA-K trisodium (E)-but-2-enedioate (E)-4-hydroxy-4-oxobut-2-enoate Chemical compound [Na+].[Na+].[Na+].OC(=O)\C=C\C([O-])=O.[O-]C(=O)\C=C\C([O-])=O JYXKLAOSCQDVIX-NFMYELBMSA-K 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to a preparation technology of adult cell-derived organoids. The invention generates the monoclonal antibody of anti-GSK-3 beta by screening specific antigen epitope and by a proprietary hybridoma technology. The antibodies reported in the present invention have high binding affinity; the protein is specifically combined with GSK-3 beta human protein, and has no cross reaction; can effectively inhibit the expression of GSK-3 beta, can promote the mesenchymal stem cells of the bone marrow to construct kidney-like organs, can also promote the iPSC to be differentiated into neural stem cells, and has good application prospect.
Description
Technical Field
The invention relates to the field of biology, in particular to a preparation technology of an adult cell-derived organoid.
Background
Organoids (Organoids), meaning that it resembles an organ of tissue. In fact, it is itself a model based on 3D in vitro cell culture systems, highly similar to the source tissue or organ in vivo. These 3D in vitro culture systems replicate the complex spatial morphology of differentiated tissues and are capable of exhibiting cell-to-cell interactions and spatial position morphology between cells and their surrounding matrix. But also can achieve the physiological reaction similar to the tissue and organ differentiated in the body, and has extremely high similarity to the source tissue. Compared with the traditional 2D cell culture mode, the organoids cultured in 3D comprise various cell types, can form functional 'micro-organs', and can be better used for simulating the generation process and the physiological and pathological states of organ tissues, so that the organoids have wide application prospects in the aspects of basic research and clinical diagnosis and treatment.
Organoids are used for physiological studies, and the material can be derived from pluripotent stem cells (hPSCs) or adult stem cells. The pluripotent stem cells can be derived from Embryonic Stem Cells (ESCs) and Induced Pluripotent Stem Cells (iPSCs), while the somatic stem cells are generally derived from separation and purification of tissue samples obtained by surgical operation. Besides physiological research such as embryonic development, normal tissue organoids can also be applied to tumor research, including mechanism research of carcinogenic risk factors and establishment of tumor organoids under gene editing conditions.
Research on organoids has focused on disease models, such as developmental related problems, genetic diseases, tumor cancer, and the like. By using the iPSCs of the patient, a valuable disease model can be established, and the disease model of the patient can be simulated and reproduced in vitro; meanwhile, the establishment of the organoids can realize more effective and more real detection on the drug effect and toxicity of the drug. Because the organoids can be directly cultured and generated by the human iPSCs, the inconsistency of detection results caused by the difference between the animal and human cells is avoided to a great extent compared with an animal model.
It has been shown that stem cells can be induced to differentiate into collecting ducts and nephrons by directed differentiation. Ureteric buds also originate in the mesoderm and interact with an adjacent cell population (i.e., metanephric mesenchyme), which will give rise to the ureteric tree, forming the ureter, renal pelvis, and collecting ducts, while metanephric mesenchymal progenitor cells give rise to nephrons. Ureteral epithelium is derived from one side branch of the mesonephron duct, which itself forms in the anterior mesoderm, while the posterior mesenchyme is derived from the posterior mesoderm. Cells migrate from the primitive streak (somite mesoderm) cephalically to form the mesoderm. Early migrating primitive streak cells form ureteric epithelium under the stimulation of fibroblast growth factor 9(fibroblast growth factor9, FGF9), while selective inhibitors of liver glycogen synthesis kinase3 β receptor (CHIR99021) stimulate later migrating primitive streak cells by altering the duration of Wnt signaling, causing increased metanephric mesenchyme. According to this principle, in 2015 foreign scholars obtained kidney-like organs by inducing the directed induced differentiation of pluripotent stem cells. The Xiaofenglin and the like successfully construct kidney-like organs by adopting BM-MSCs, utilizing selective inhibitors of CHIR99021 hepatic glycogen synthetic kinase3 beta receptors and controlling the differentiation of the BM-MSCs through cytokines. It follows that liver glycogen synthesis kinase3 β is a key step in organoid formation.
Glycogen synthase kinase-3 (GSK-3) is an evolutionarily well-conserved serine/threonine kinase that is ubiquitous in mammalian eukaryotic cells, and in addition to the earliest findings of regulation of Glycogen Synthase (GS) activity, GSK-3 β acts on numerous signaling proteins, structural proteins and transcription factors to regulate cell differentiation, proliferation, survival and apoptosis. In the research of various serious diseases such as cancer, neurodegenerative diseases, neuropsychiatric diseases and the like, the selection of the compound as a therapeutic target is receiving attention from more and more researchers. Inhibitors of the liver glycogen synthesis kinase3 β pathway currently exist in a few classes and are not available in a wide variety of alternative classes.
Disclosure of Invention
The invention provides a monoclonal antibody with specificity aiming at GSK-3 beta. The antibody is obtained by screening specific dominant antigen epitope.
In one aspect, the invention provides a GSK-3 β -D8 monoclonal antibody having an affinity dissociation constant (Kd) of 5.17 × 10-10And belongs to high affinity antibodies.
The light and heavy chain sequences of the monoclonal antibodies are respectively as follows:
light chain variable region (SEQ ID NO: 2)
DIVITQRPALMAASPGEKVTITCNKKECMKVQMCAWYQQKSGISPKPWIYHFAHNSYGVPARFSGSGSGTSYSLTITSMEAEDAATYYCTGWYLNFKGFGAGTKLELK
Heavy chain variable region (SEQ ID NO: 3)
EVQLEESATELARPGASVKLSCKASGYIFSACLYPWIKQRPGQGLEWIGGLPIMCFLPQRENNHMGKATLTADKSSSTAYMQLSSLASEDSAVYYCAGEYYASANWGLGTTLAVSS。
Preferably, the amino acid sequence of the heavy chain variable region is an analogous sequence having at least 50% homology to sequence 3, preferably, the amino acid sequence of the heavy chain variable region is an analogous sequence having at least 60% homology to sequence 3, preferably, the amino acid sequence of the heavy chain variable region is an analogous sequence having at least 70% homology to sequence 3, preferably, the amino acid sequence of the heavy chain variable region is an analogous sequence having at least 80% homology to sequence 3, preferably, the amino acid sequence of the heavy chain variable region is an analogous sequence having at least 90% homology to sequence 3, preferably, the amino acid sequence of the heavy chain variable region is an analogous sequence having at least 99% homology to sequence 3.
Preferably, the amino acid sequence of the light chain variable region is an analogous sequence having at least 50% homology to sequence 2, preferably, the amino acid sequence of the light chain variable region is an analogous sequence having at least 60% homology to sequence 2, preferably, the amino acid sequence of the light chain variable region is an analogous sequence having at least 70% homology to sequence 2, preferably, the amino acid sequence of the light chain variable region is an analogous sequence having at least 80% homology to sequence 2, preferably, the amino acid sequence of the light chain variable region is an analogous sequence having at least 90% homology to sequence 2, preferably, the amino acid sequence of the light chain variable region is an analogous sequence having at least 100% homology to sequence 2.
The present disclosure includes nucleic acid molecules encoding the immunoglobulin light and heavy chain genes of GSK-3 β monoclonal antibodies, vectors comprising such nucleic acids, and host cells capable of producing the anti-GSK-3 β monoclonal antibodies of the present disclosure.
The GSK-3 β monoclonal antibodies of the invention may be prepared by recombinant expression of immunoglobulin light and heavy chain genes in a host cell. For recombinant expression of the antibody, the host cell is transfected with one or more recombinant expression vectors carrying DNA fragments encoding the immunoglobulin light and heavy chains of the antibody, such that the light and heavy chains are expressed in the host cell, optionally secreted into the medium in which the host cell is cultured, from which medium the antibody can be recovered. Antibody heavy and light chain genes are obtained using standard recombinant DNA methods, integrated into recombinant expression vectors, and the vectors introduced into host cells.
GSK-3 β monoclonal antibodies of the present disclosure include intact molecules and antibody fragments (e.g., fragments of Fab and F (ab ')2 that specifically bind hpg. Fab and F (ab')) 2 fragments lack the Fc fragment of an intact antibody, clear more rapidly from the circulation of an animal or plant, and may have less non-specific tissue binding than an intact antibody. Thus, the antibody fragments may be used for therapeutic applications among other applications.
The term "antibody fragment" refers to a portion of a full-length antibody, typically the target binding or variable region. Examples of antibody fragments include Fab, Fab ', F (ab')2 and Fv fragments. An "Fv" fragment is the smallest antibody fragment that contains the entire target recognition and binding site. This region consists of a dimer of one heavy and one light chain variable domain (V1, V2) in close, non-covalent association. H-VL in this configuration, the three CDRs of each variable domain interact to define a target binding site on the surface of V. H-VL dimer. Typically, six CDRs confer antibody target binding specificity. However, in some cases, even a single variable domain (or half of an Fv comprising only three CDRs specific for a target) can have the ability to recognize and bind a target, albeit with a lower affinity than the entire binding site. "Single chain Fv" or "scFv" antibody fragments comprise the domains of VH and VL antibodies, wherein these domains are present in a single polypeptide chain. Typically, the Fv polypeptide further comprises a polypeptide linker between Vv and Vb. H and VL enable the scFv to form domains of the desired structure for target binding. A "single domain antibody" is a domain that displays sufficient affinity for HPG by a single VH or VL.
The GSK-3 β monoclonal antibody may be formulated in a composition. Optionally, the compositions provided herein are typically provided as part of a sterile pharmaceutical composition, which typically includes a pharmaceutically acceptable carrier. The composition may be in any suitable form (depending on the desired method of administration to the patient).
In another aspect of the invention, the use of a GSK-3 β monoclonal antibody in the preparation of a pharmaceutical composition for inhibiting GSK-3 β activity is provided.
The GSK-3 β monoclonal antibodies of the invention may be administered to a patient by a variety of routes, such as oral, transdermal, subcutaneous, intranasal, intravenous, intramuscular, intraocular, topical, intrathecal and intracerebroventricular. In any given case, the most suitable route of administration will depend on the particular antibody, the subject, the nature and severity of the disease and the physical condition of the subject. The antibody can be formulated as an aqueous solution for administration by subcutaneous injection.
The pharmaceutical compositions may conveniently be presented in unit dosage form comprising a predetermined amount of an anti-GSK-3 β monoclonal antibody of the present disclosure per dose. Such units may comprise, for example, but are not limited to, 5mg to 5g, such as 10mg to 1g, or 20mg to 50 mg. Pharmaceutically acceptable carriers for use in the present disclosure may take a variety of forms, for example, depending on the condition to be treated or the route of administration.
By mixing the antibody having a desired purity with an optional pharmaceutically acceptable carrier, excipients or stabilizers (all of which are referred to herein as "carriers"), which are commonly used in the art, i.e., buffers, stabilizers, preservatives, isotonic agents, nonionic detergents, antioxidants and other various additives, are used. These additives must be non-toxic to recipients at the dosages and concentrations employed.
Buffering agents help to maintain the pH in a range near physiological conditions. They may be present at a concentration of about 2mM to about 50 mM. Suitable buffers for use in the present disclosure include organic and inorganic acids and salts thereof, such as citrate buffers (e.g., monosodium citrate-disodium citrate mixture, trisodium citrate mixture, monosodium citrate-citrate mixture, etc.), succinate buffers (e.g., succinic acid-monosodium succinate mixture, succinic acid-sodium hydroxide mixture, succinic acid-disodium succinate mixture, etc.), tartrate buffers (e.g., tartaric acid-sodium tartrate mixture, tartaric acid-potassium tartrate mixture, tartaric acid-sodium hydroxide mixture, etc.), fumarate buffers (e.g., fumaric acid-monosodium fumarate mixture, fumaric acid-disodium fumarate mixture, monosodium fumarate-disodium fumarate mixture, etc.), gluconate buffers (e.g., gluconic acid-sodium gluconate mixture, gluconic acid-sodium hydroxide mixture, gluconic acid-potassium gluconate mixture, etc.), oxalate buffers (e.g., oxalic acid-sodium oxalate mixture, oxalic acid-sodium hydroxide mixture, oxalic acid-potassium oxalate mixture, etc.), lactate buffers (e.g., lactic acid-sodium lactate mixture, lactic acid-sodium hydroxide mixture, lactic acid-potassium lactate mixture, etc.), and acetate buffers (e.g., acetic acid-sodium acetate mixture, acetic acid-sodium hydroxide mixture, etc.). In addition, phosphate buffers, histidine buffers and trimethylamine salts such as Tris can be used.
In another aspect of the invention, the invention provides the use of the GSK-3 β monoclonal antibody in promoting bone marrow mesenchymal stem cells to construct kidney-like organs.
Further, the concentration of the GSK-3 beta monoclonal antibody in the application is 10 mu mol/L.
Furthermore, the monoclonal antibody of the invention can also promote iPSC to differentiate into neural stem cells, thereby being beneficial to the subsequent preparation of neural-related organoids.
Advantageous effects
The invention has the advantages that the monoclonal antibody of anti-GSK-3 beta is generated by screening specific antigen epitope and a special hybridoma technology. The antibodies reported in the present invention have high binding affinity; the protein is specifically combined with GSK-3 beta human protein, and has no cross reaction; can effectively inhibit the expression of GSK-3 beta, can promote the mesenchymal stem cells of the bone marrow to construct kidney-like organs, can also promote the iPSC to be differentiated into neural stem cells, and has good application prospect.
Drawings
FIG. 1 is a GSK-3 beta antigen dominant epitope analysis result diagram
FIG. 2 is a graph showing the effect of the antibody on GSK-3. beta. protein expression
FIG. 3 is a graph showing the effect of the antibody on the differentiation of iPSC into neural stem cell density
Detailed Description
The present invention will be further described below by way of specific embodiments and experimental data. Although specific terms are used below for the sake of clarity, these terms are not meant to define or limit the scope of the invention.
EXAMPLE 1 preparation of GSK-3 beta monoclonal antibody
According to the amino acid sequence of human Glycogen Synthase Kinase-3 Beta, the epitope analysis was performed, and the dominant epitope was selected as follows by computer Parker software analysis (as shown in FIG. 1):
kvsrdkgsk vttvvatpgq gpdrpqevsy tdtkvigngs fgvvyqaklc dsgelvaikk vlqdkrfknnr elqimrkldh cnivrryff ysgekkdev (SEQ ID NO: 1). The antigen was artificially synthesized and used for the following immunization.
(1) Primary immunization: taking 4 healthy female BALB/c mice of 6 weeks old, diluting 800 mu g of GSK-3 beta antigen fragment with 100 mu l of sterile PBS, mixing with 100 mu l of complete Freund's adjuvant, fully emulsifying, and injecting into the abdominal cavity of each mouse;
(2) and (3) second immunization: after three weeks, diluting 80 μ g of GSK-3 β antigen fragment with 100 μ l of sterile PBS, and mixing with 100 μ l of incomplete Freund's adjuvant by emulsifying, and injecting into abdominal cavity of each mouse;
(3) blood is taken from orbital venous plexus of mice, the serum titer is determined by an indirect ELISA method, and the selected serum titer reaches 1:105The mice were subjected to intraperitoneal injection and impact immunization 1 time after being diluted with 200. mu.g of GSK-3 beta antigen fragment without adjuvant in 100. mu.l of PBS 3 days before cell fusion;
(4) BALB/c mouse spleen cells were taken three days later for cell fusion.
(5) Myeloma cells Sp2/0 at logarithmic growth phase are centrifuged at 1000rpm for 5min, the supernatant is discarded, the cells are resuspended in 10ml serum-free RPMI-1640 complete medium and counted, and the cell number is adjusted to 1X107Washing with serum-free RPMI-1640 complete medium for 2 times;
(6) sp2/0 myeloma cells were mixed with spleen cells in a ratio of 1:1(V/V) in 50ml plastic cone-bottom centrifuge tubes. Filling a centrifugal tube with serum-free RPMI-1640 complete culture medium, and centrifuging at 1000rpm for 5mim at room temperature;
(7) preheating 50% PEG solution and serum-free RPMI-1640 complete medium;
(8) sucking the centrifuged mixed cell supernatant, adding 1ml of hot PEG into the mixed cell sediment, slowly adding dropwise at a constant speed within 1min, gently stirring the cells by using a pipettor every time one drop is added, and gently stirring the cells for 1min after the dropwise addition is finished;
(9) adding preheated serum-free RPMI-1640 complete culture medium into the mixed cell liquid drop by drop, slightly stirring while adding, stopping the PEG effect, adding lml, 2ml, 3ml, 4ml, 5ml and 10ml respectively every 2 minutes, and finally supplementing the serum-free RPMI-1640 complete culture medium to 50 ml;
(10) centrifuging at 1000rpm for 5 mm, discarding the supernatant, adding 5ml HAT culture medium, slightly blowing and sucking the precipitated cells, and cutting to prevent the cells fused together from scattering;
(11) supplemented with HAT and RPMI-1640 complete Medium and 1% MagicTMCloning factor of hybridoma cell, adding fused cell suspension into 5 96-well plates, 1 × 105The cells/(150. mu.l/well) were placed in a 37 ℃ cell incubator with 5% CO2And culturing under saturated humidity condition.
(12) On 14 th day after fusion, collecting the supernatant of the fused cells for detection, screening positive clones by an indirect ELISA method, and taking the culture supernatant of myeloma cell Sp2/0 as a negative control; and co-screening 17 hybridoma cells with better positive, further cloning by a limiting dilution method, and selecting two hybridoma cell strains with strongest positive for stable expression, namely GSK-3 beta-C1 and GSK-3 beta-D8 for later use.
The screened sheetsCloning of cell lines to 106Ascites was prepared by injecting each cell/mouse abdominal cavity. When the ascites of the mouse is generated to the maximum, the neck of the mouse is removed, the mouse is killed, the ascites is collected, and the ascites antibody titer is detected by an indirect ELISA method. The antibody in the ascites was purified by the ammonium caprylate method and protein A column.
Detecting the purity and concentration of the antibody by SDS-PAGE and ultraviolet spectrophotometry; the results of subtype identification of the monoclonal antibody using the mouse antibody subtype identification kit are shown in Table 1.
TABLE 1 antibody concentrations and subtypes
Hybridoma cell | Antibody concentration (mg/mL) | Cell subsets |
GSK-3β-C1 | 12.11±0.55 | IgG1 |
GSK-3β-D8 | 15.32±0.67 | IgG2a |
To verify the specificity of the obtained 2 monoclonal antibodies, the two antibodies were separately combined with SEQ ID NO: 1. comparison of recombinant human GSK-3 beta (Biovision, Cat number: 7004-100) and GSK-3 beta additional antigen fragments sidvwsagcv laelllgqpipfgdgvsdvqlveikvlgtptreqirmernp, HCG and BSA after indirect ELISA detection shows that the cross-reactivity rate of 2 monoclonal antibodies obtained by screening is less than 0.1 percent, and the monoclonal antibodies can specifically react with GSK-3 beta holoprotein and the immunogen fragment of the invention, which shows that the specificity is better (Table 2).
TABLE 2 Cross-reactivity of antibodies
Example 2 identification of the affinity and sequence characteristics of the GSK-3 beta-D8 monoclonal antibody
Measuring the affinity of the monoclonal antibody by using an indirect ELISA method, namely coating an ELISA plate with 2 mu g/mL GSK-3 beta protein, sealing, adding the monoclonal antibody diluted and purified in a multiple ratio, taking goat anti-mouse IgG marked by HRP as a secondary antibody, and reading OD (origin-destination-diameter) by using an ELISA reader450The absorbance at nm, calculated according to the conventional data processing method in the field (A practical guide to monoclonal antibodies), gave GSK-3 beta-D8 monoclonal antibody affinity dissociation constant (Kd) of 5.17X 10-10And belongs to high affinity antibodies.
The light and heavy chain sequences of the monoclonal antibody obtained by amplifying the light and heavy chain sequences of the antibody by using a PCR method and identifying through sequencing are respectively as follows:
light chain variable region (SEQ ID NO: 2)
DIVITQRPALMAASPGEKVTITCNKKECMKVQMCAWYQQKSGISPKPWIYHFAHNSYGVPARFSGSGSGTSYSLTITSMEAEDAATYYCTGWYLNFKGFGAGTKLELK
Heavy chain variable region (SEQ ID NO: 3)
EVQLEESATELARPGASVKLSCKASGYIFSACLYPWIKQRPGQGLEWIGGLPIMCFLPQRENNHMGKATLTADKSSSTAYMQLSSLASEDSAVYYCAGEYYASANWGLGTTLAVSS。
Example 3 Effect of the monoclonal antibody GSK-3 beta-D8 on GSK-3 beta
Human colon cancer cells HT-29(HT29), cells in logarithmic growth phase digested with 0.25% pancreatin, and digested with 2X108cells/L were inoculated into 6-well plates at a density of cells/L, monoclonal antibodies (0, 1, 10, 100. mu. mol/L) at different concentrations were added after 36 hours, BIO (1. mu. mol/L, CAS No.: 667463-62-9, sigma) was used as a positive control, the culture was continued for 20 hours, cells of each group were collected by digestion with 0.25% trypsin without EDTA, and PBS was centrifuged and resuspended 1 time. Detecting GSK-3 beta protein expression by Western blotting: extracting total cell eggs according to the operation steps of the protein extraction kitAnd (3) white and determining the protein concentration, adding 20 mu g of total protein into each lane for SDS-PAGE electrophoresis, transferring the protein to an NC membrane by wet transfer, sealing the NC membrane by 5% skimmed milk powder at room temperature for 1h, adding mouse anti-GSK-3 beta (1: 100), incubating the protein overnight in a shaking table at 4 ℃, washing the membrane by TBS-T for 10minx3 times, adding corresponding horse radish peroxidase labeled goat anti-mouse and goat anti-rabbit IgG (1: 4000), incubating the protein in the shaking table at room temperature for 1h, washing the membrane by TBS-T for 10min x3 times, and then developing the color by an ECL chemiluminescence system. Scanning a film, analyzing a gray value by QuantityOne software, and calculating the relative protein content of the GSK-3 beta by taking the expression quantity of the beta-actin as the basis of the relative expression quantity. The experiment was repeated 3 times. The results are shown in FIG. 2.
As can be seen from the Western blotting detection results in FIG. 2, the differences between the D8 monoclonal antibody and the positive control group are statistically significant (P <0.05), and after treatment with 100. mu. mol/L D8 monoclonal antibody, the relative expression level of GSK-3 beta is only (0.02 + -0.01), which is significantly improved compared with the positive control (0.35 + -0.04). From the above results, it can be seen that the GSK-3 β -D8 monoclonal antibody provided by the present invention can significantly inhibit the activity of GSK-3 β protein.
Example 4 Effect of GSK-3. beta. -D8 monoclonal antibody on the differentiation of iPSC into neural stem cells
iPSC cell (A)iPSM0041, triple starter) were inoculated into Matrigel-coated 6-well plates and mTeSR was addedTM1 pluripotent stem cell culture medium for 1 Day, the next Day (Day1) was changed to neural differentiation medium (DMEM/F12 and NeurobasalMedium mixed at 1:1, and 0.5 XN 2, 0.5 XB 27, 0.1mmol/Lascorbicacid, 1 XGlutamax, 1 XAntibi-otic-antiviral). At this stage, the Smad inhibitors SB and DMH1 that favour the differentiation of ipscs towards the ectoderm were added. Meanwhile, in order to study the influence of the GSK-3 beta-D8 monoclonal antibody on the differentiation of iPSC, the GSK-3 beta-D8 monoclonal antibody with different concentrations is added, 4 experimental groups with the concentration of 0, 1, 10 and 100 mu mol/L (mu M) are divided according to different concentrations, the 0 mu mol/L group is used as a control group, the positive control is BIO (1 mu mol/L, CAS number: 667463-62-9, sigma), the culture is carried out for 6D, and the liquid is changed every other day. Respective measurement of cell concentration "cell count in units of 1 well of 6-well plate(Unit 10)6Individual/well) "and NSC markers SOX1, Nestin. The results are shown in FIG. 3.
As can be seen from the results in FIG. 3, the higher the concentration of the monoclonal antibody added to the experimental group, the more the cells are aggregated, the greater the number of cells, and the number of cells in the 1. mu. mol/L D8 monoclonal antibody group is (0.73. + -. 0.06). times.106The number of cells was (0.65. + -. 0.06). times.10 in comparison with the positive control group6The differentiation and proliferation promoting effect is obvious; the number of the monoclonal antibody group cells of 100 mu mol/L D8 is (1.70 +/-0.05) multiplied by 106The proliferation was most pronounced. The difference between the 0. mu. mol/L group and the experimental group is statistically significant (P)<0.05). In addition, immunofluorescence results showed that cells of the positive control group and each experimental group expressed NSC markers SOX1, Nestin. Indicating that each set of ipscs had differentiated into NSCs. Wherein the average positive rate of the 1 mu mol/L D8 monoclonal antibody group is 92.75 percent, which is slightly improved than the positive control group of 90.52 percent and is also higher than the positive rate of the high-concentration D8 monoclonal antibody. This also indicates that ipscs differentiated into NSCs, with higher concentrations of mab giving greater cell densities, but the expression of high concentration set SOX1 was lower than the other sets. The D8 monoclonal antibody is suggested to make cell proliferation more vigorous, and the differentiation was not affected by a certain concentration of monoclonal antibody (1. mu. mol/L), but not by a high concentration of D8 monoclonal antibody.
Example 5 bone marrow mesenchymal stem cell construction of Kidney-like organ experiment
The bone marrow mesenchymal stem cells (CP-H166, Wuhan Pronoch Life technologies, Ltd.) are cultured by using DMEM/F-12 liquid medium containing 10% fetal calf serum, after passage, the confluency is 40-50% after passage in 2-3d, DMEM/F-12 liquid medium containing 10% fetal calf serum in a culture dish is removed, APEL liquid medium containing 10 mu mol/L D8 monoclonal antibody is added, the culture is carried out for 4d at 37 ℃, and the culture medium is replaced every 2 d. After 4 days, the medium was changed to APEL broth containing 200ng/ml FGF9+ 1. mu.g/ml heparin. Culture was carried out at 37 ℃ until day 7, and medium was changed every 2 days. On day 7, after digesting the cells with trypsin, the cells were centrifuged at 400g for 3min and resuspended in 3ml of pure APEL liquid medium. About 5X 10 per kidney-like organ is required5For each cell, the required amount of cell suspension was pipetted into a 1.5ml Eppendorf tube. Centrifuge 400g for 2min, discard supernatant, only 1 cell pellet left. APEL liquid medium containing 10. mu. mol/L of monoclonal antibody was added to a Transwell plate. The Transwell filter was attached to the surface of the medium. The cell pellet was placed on a Transwell filter. Incubate 1h at 37 ℃ and change to 1.2ml APEL broth containing 200ng/ml FGF9+ 1. mu.g/ml heparin for 5 days, change the medium every 2 days and change to pure APEL broth on day 12. Medium was changed every 2d and kidney-like organs were cultured in pure APEL liquid medium to day 25. The control group uses CHIR99021 to replace the monoclonal antibody of the invention. The results show that, in the kidney-like organs, fluorescence markers of distal tubule (ECAD +), proximal tubule (LTL +), glomerulus (WT1+) and blood vessel (CD31) can be detected no matter in the experimental group or the control group, which indicates that the kidney-like organs are primarily formed, and the antibody of the present invention can control the formation ratio of the metanephric mesenchyme by regulating Wnt signals, so as to finally control the formation of nephrons. The results show that the D8 monoclonal antibody of the invention has basically similar action with CHIR99021, and can be used for constructing kidney-like organs by using mesenchymal stem cells.
In view of the many possible embodiments to which the principles of the disclosed invention may be applied, it should be recognized that the illustrated embodiments are only preferred embodiments of the invention and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the appended claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.
Sequence listing
<110> Nosai Union (Beijing) biomedical science and technology Co., Ltd
<120> technology for preparing organoid derived from adult cells
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 100
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Lys Val Ser Arg Asp Lys Asp Gly Ser Lys Val Thr Thr Val Val Ala
1 5 10 15
Thr Pro Gly Gln Gly Pro Asp Arg Pro Gln Glu Val Ser Tyr Thr Asp
20 25 30
Thr Lys Val Ile Gly Asn Gly Ser Phe Gly Val Val Tyr Gln Ala Lys
35 40 45
Leu Cys Asp Ser Gly Glu Leu Val Ala Ile Lys Lys Val Leu Gln Asp
50 55 60
Lys Arg Phe Lys Asn Arg Glu Leu Gln Ile Met Arg Lys Leu Asp His
65 70 75 80
Cys Asn Ile Val Arg Leu Arg Tyr Phe Phe Tyr Ser Ser Gly Glu Lys
85 90 95
Lys Asp Glu Val
100
<210> 2
<211> 108
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Asp Ile Val Ile Thr Gln Arg Pro Ala Leu Met Ala Ala Ser Pro Gly
1 5 10 15
Glu Lys Val Thr Ile Thr Cys Asn Lys Lys Glu Cys Met Lys Val Gln
20 25 30
Met Cys Ala Trp Tyr Gln Gln Lys Ser Gly Ile Ser Pro Lys Pro Trp
35 40 45
Ile Tyr His Phe Ala His Asn Ser Tyr Gly Val Pro Ala Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Thr Ser Met Glu
65 70 75 80
Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Thr Gly Trp Tyr Leu Asn Phe
85 90 95
Lys Gly Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105
<210> 3
<211> 116
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Glu Val Gln Leu Glu Glu Ser Ala Thr Glu Leu Ala Arg Pro Gly Ala
1 5 10 15
Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Ser Ala Cys
20 25 30
Leu Tyr Pro Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Gly Leu Pro Ile Met Cys Phe Leu Pro Gln Arg Glu Asn Asn His
50 55 60
Met Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80
Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Gly Glu Tyr Tyr Ala Ser Ala Asn Trp Gly Leu Gly Thr Thr Leu
100 105 110
Ala Val Ser Ser
115
Claims (6)
1. A monoclonal antibody D8 specific for GSK-3 beta, the light and heavy chain sequences of the antibody are respectively as follows:
the light chain variable region has the sequence shown in SEQ ID NO: 2, the sequence of the heavy chain variable region is shown as SEQ ID NO: 3, respectively.
2. Use of the monoclonal antibody D8 of claim 1 in the preparation of a pharmaceutical composition for inhibiting GSK-3 β activity.
3. The use according to claim 2, wherein said composition further comprises a pharmaceutically acceptable carrier.
4. Use according to claim 3, characterized in that the carrier is an excipient or stabilizer commonly used in the art.
5. Use of the GSK-3 β monoclonal antibody D8 of claim 1 for promoting the differentiation of ipscs into neural stem cells.
6. Use of the GSK-3 β monoclonal antibody D8 of claim 1 for promoting bone marrow mesenchymal stem cells in the construction of a kidney-like organ.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210539273.8A CN114702591B (en) | 2022-05-17 | 2022-05-17 | Preparation technology of adult cell-derived organoid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210539273.8A CN114702591B (en) | 2022-05-17 | 2022-05-17 | Preparation technology of adult cell-derived organoid |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114702591A true CN114702591A (en) | 2022-07-05 |
CN114702591B CN114702591B (en) | 2022-09-23 |
Family
ID=82175685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210539273.8A Active CN114702591B (en) | 2022-05-17 | 2022-05-17 | Preparation technology of adult cell-derived organoid |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114702591B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117362441A (en) * | 2023-12-08 | 2024-01-09 | 再少年(北京)生物科技有限公司 | Method for inducing directional differentiation of iPS into kidney-like organ and application |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060121040A1 (en) * | 2004-12-08 | 2006-06-08 | Wisconsin Alumni Research Foundation | Compositions and methods for treating neuroendocrine tumors |
CN101193859A (en) * | 2005-06-14 | 2008-06-04 | 先灵公司 | The preparation and use of compounds as protease inhibitors |
US20110081659A1 (en) * | 2009-09-28 | 2011-04-07 | Rodriguez-Suarez Roberto J | Substrates for glycogen synthase kinase 3 enzymes and methods of use |
CN102552269A (en) * | 2012-02-14 | 2012-07-11 | 上海日馨生物科技有限公司 | Application of SBT as inhibitor of GSK-3beta |
CN104694570A (en) * | 2008-03-17 | 2015-06-10 | 斯克里普斯研究所 | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
CN104825491A (en) * | 2009-10-28 | 2015-08-12 | 吉诺米克斯股份有限公司 | Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood |
CN105283542A (en) * | 2013-06-11 | 2016-01-27 | 国立大学法人京都大学 | Method for producing renal precursor cells, and drug containing renal precursor cells |
CN108473961A (en) * | 2015-11-04 | 2018-08-31 | 菲特治疗公司 | Method and composition for induction of hematopoiesis cell differentiation |
CN109294991A (en) * | 2018-11-07 | 2019-02-01 | 北京赛贝生物技术有限公司 | The method of differentiation of neural stem cells culture medium and differentiation of neural stem cells |
CN110662832A (en) * | 2017-05-25 | 2020-01-07 | 国立大学法人京都大学 | Method for inducing renal progenitor cells by differentiation of mesodermal cells and method for inducing renal progenitor cells by differentiation of pluripotent stem cells |
-
2022
- 2022-05-17 CN CN202210539273.8A patent/CN114702591B/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060121040A1 (en) * | 2004-12-08 | 2006-06-08 | Wisconsin Alumni Research Foundation | Compositions and methods for treating neuroendocrine tumors |
CN101193859A (en) * | 2005-06-14 | 2008-06-04 | 先灵公司 | The preparation and use of compounds as protease inhibitors |
CN104694570A (en) * | 2008-03-17 | 2015-06-10 | 斯克里普斯研究所 | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
US20110081659A1 (en) * | 2009-09-28 | 2011-04-07 | Rodriguez-Suarez Roberto J | Substrates for glycogen synthase kinase 3 enzymes and methods of use |
CN104825491A (en) * | 2009-10-28 | 2015-08-12 | 吉诺米克斯股份有限公司 | Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood |
CN102552269A (en) * | 2012-02-14 | 2012-07-11 | 上海日馨生物科技有限公司 | Application of SBT as inhibitor of GSK-3beta |
CN105283542A (en) * | 2013-06-11 | 2016-01-27 | 国立大学法人京都大学 | Method for producing renal precursor cells, and drug containing renal precursor cells |
CN108473961A (en) * | 2015-11-04 | 2018-08-31 | 菲特治疗公司 | Method and composition for induction of hematopoiesis cell differentiation |
CN110662832A (en) * | 2017-05-25 | 2020-01-07 | 国立大学法人京都大学 | Method for inducing renal progenitor cells by differentiation of mesodermal cells and method for inducing renal progenitor cells by differentiation of pluripotent stem cells |
CN109294991A (en) * | 2018-11-07 | 2019-02-01 | 北京赛贝生物技术有限公司 | The method of differentiation of neural stem cells culture medium and differentiation of neural stem cells |
Non-Patent Citations (3)
Title |
---|
ABBAS SHAKOORI等: "Inhibition of GSK-3β activity attenuates proliferation of human colon cancer cells in rodents", 《CANCER SCIENCE》 * |
肖枫林等: "骨髓间充质干细胞构建类肾器官实验", 《解放军医学院学报》 * |
蒋超等: "浅述干细胞治疗慢性肾疾病的潜力", 《中国比较医学杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117362441A (en) * | 2023-12-08 | 2024-01-09 | 再少年(北京)生物科技有限公司 | Method for inducing directional differentiation of iPS into kidney-like organ and application |
CN117362441B (en) * | 2023-12-08 | 2024-02-13 | 再少年(北京)生物科技有限公司 | Method for inducing directional differentiation of iPS into kidney-like organ and application |
Also Published As
Publication number | Publication date |
---|---|
CN114702591B (en) | 2022-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115028730B (en) | Preparation method of adult stem cell-derived organoid | |
CN103975078B (en) | Treatment and the method and composition of diagnosing bladder cancer | |
JPH05509312A (en) | Tissue-derived tumor growth inhibitor, method of preparation and use thereof | |
CN112679613B (en) | Application of bone marrow mesenchymal stem cells in combination with monoclonal antibody in treatment of cancer | |
CN111671896B (en) | Application of bone marrow mesenchymal stem cells and monoclonal antibody in combined treatment of cancer | |
CN114702591B (en) | Preparation technology of adult cell-derived organoid | |
WO2022166802A1 (en) | Anti-human cd271 monoclonal antibody | |
CN106414726A (en) | Anti-NME antibody | |
Sugimoto et al. | Alpha‐smooth‐muscle actin and desmin expressions in human neuroblastoma cell lines | |
CN117050183B (en) | Blocking antibody of PTN-PTPRZ1 pathway and application of blocking antibody in glioma targeted therapy | |
CN109071668A (en) | The antibody of anti-N- acerylglucosamine and GalNAc | |
CN111732660B (en) | Combined treatment of cancer by mesenchymal stem cells and monoclonal antibodies | |
CN109666074A (en) | A kind of purposes of chemokine receptors CXCR5 | |
CN116514975B (en) | Mouse anti-human B7-H3 monoclonal antibody, preparation method and application thereof | |
CN115975035B (en) | Use of stem cells and antibodies in combination for the treatment of cancer | |
CN107556386A (en) | Anti- EGFRvIII and CD3 specificity double targeting antibodies, the minicircle dna containing double targeting antibodies expression cassettes and applications | |
CN112553156B (en) | Method for effectively improving production of mesenchymal stem cell cytokines | |
CN100465279C (en) | Prepn and application of epiderm or hair follicle stem cell from souce of human early embryo | |
CN109337903A (en) | Long-chain non-coding RNA lncRNA-6585, antibody and application thereof | |
CN105646704B (en) | Anti- p185erbB2 human mouse chimeric antibody ChAb26, mammary gland specific expression vector, transgenosis FVB mouse and preparation method thereof | |
CN114196676A (en) | Application of ITGA2 gene in regulation and control of pig beige adipogenesis | |
CN115975036B (en) | Pharmaceutical composition comprising stem cells and use thereof for treating cancer | |
CN112920994B (en) | Production method for promoting yield of stem cell cytokines | |
CA2351585A1 (en) | Influencing of angigenesis using cd66a | |
JP2961237B2 (en) | Fibroblast growth factor-1 monoclonal antibody and method for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |